The EFFORT needed to overcome PARP resistance in ovarian cancer
Adavosertib with or without olaparib demonstrated clinical activity with a manageable toxicity...
Read MoreJul 8, 2021
Adavosertib with or without olaparib demonstrated clinical activity with a manageable toxicity...
Read MoreJul 7, 2021
“He was unhappy to learn that I had prescribed a placebo, but when I told him it was an...
Read MoreJul 1, 2021
For a presentation at ASCO 2021, John Seymour, PhD, Professor at the Peter MacCallum Cancer Centre of the Royal Melbourne Hospital and University of Melbourne in Australia, discussed six FDA-approved agents or drug...
Read MoreJul 1, 2021
For a review presented at ASCO 2021, Sonali M. Smith, MD, FASCO, Elwood V. Jensen Professor in Medicine and Chief of the Section of Hematology/Oncology at the University of Chicago, discussed the findings of two studies focused...
Read MoreJul 1, 2021
TG-1701 (TG Therapeutics) is an investigational, once-daily, selective, convalent, oral Bruton tyrosine kinase inhibitor. Prior research has shown that inhibition of Bruton tyrosine kinase is superior to standard...
Read MoreJul 1, 2021
Genetic testing for BRCA1/2 mutations is recommended for all women with ovarian cancer, given the important implications for treatment and prognosis, according to the Caitlin E. Taylor, MD, lead author of a paper presented at...
Read MoreJul 1, 2021
It has long been identified that Black women with ovarian cancer have worse overall survival when compared to White women, explains Deanna L Huffman, DO, Department of Internal Medicine, Allegheny Health Network, in Pittsburgh....
Read MoreJul 1, 2021
Effective patient-clinician communication (PCC) is central to the delivery of high-quality care, according to the National Cancer Institute (NCI), and it becomes even more crucial in the cancer setting where patients deal with...
Read MoreJul 1, 2021
A better understanding of the burden of treatment side effects in patients with gynecological malignancies could help guide symptom interventions and oncologic therapy decision-making, according to Ashley D. Hickman, MD, the...
Read MoreJul 1, 2021
Adavosertib with or without olaparib shows efficacy in women with PARP inhibitor-resistant ovarian cancer (Abstract #5505) Clinical trial results from the randomized, non-comparative Phase II EFFORT study showed that...
Read MoreJul 1, 2021
Median overall survival doubled for veterans with stage 3 non-small cell lung cancer who received chemoradiotherapy plus durvalumab, as compared to those receiving chemoradiotherapy alone, according to a new study presented at...
Read MoreJul 1, 2021
The phase 3 ELEVATE-RR trial was a head-to-head comparison of acalabrutinib versus ibrutinib in...
Read MoreJun 25, 2021
JUNE 25, 2021 SEASON: 1 EPISODE: 19
Read MoreJun 25, 2021
This week’s thought leaders include: In a...
Read MoreJun 23, 2021
A study evaluating the utility of novel imaging biomarkers (radiomics) to distinguish patients...
Read MoreJun 23, 2021
Since the 1950s, when the movement disorder tardive dyskinesia (TD) was first described, several drugs have been studied for potential effectiveness or used off-label for the treatment of TD, but none provided clear evidence of...
Read MoreJun 23, 2021
Final results from the head-to-head ELEVATE-RR Phase III trial of acalabrutinib demonstrated non-inferior progression-free survival (PFS) and statistically significantly fewer events of atrial fibrillation versus ibrutinib in...
Read MoreJun 23, 2021
The phase III PAOLA-1/ENGOT-ov25 trial evaluated the addition of maintenance olaparib to bevacizumab in women with advanced ovarian cancer who were in response after first-line platinum-based CTx with bevacizumab. In the Phase...
Read MoreJun 23, 2021
Clinical trial results from the randomized, non-comparative Phase II EFFORT study showed that adavosertib, a Wee1 inhibitor, was effective in patients with PARP inhibitor-resistant ovarian cancer when given alone and in...
Read More